IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-8.33%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$219M
AUM Growth
+$219M
(-21%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-13.33%
Top 10 Holdings %
Top 10 Hldgs %
60.72%
Holding
71
New
8
Increased
9
Reduced
20
Closed
15
Top Buys
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$7.63M |
| 2 |
PTC Therapeutics
PTCT
|
$6.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$5.9M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$5.53M |
| 5 |
Eli Lilly
LLY
|
$2.77M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$10.8M |
| 2 |
STML
Stemline Therapeutics, Inc.
STML
|
$10.3M |
| 3 |
Illumina
ILMN
|
$8.32M |
| 4 |
Gilead Sciences
GILD
|
$4.18M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$3.71M |
Sector Composition
| 1 | Healthcare | 96.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$100B
| $18.5M | 8.44% | 77,822 -15,600 | -17% | -$3.71M |
|
|
2
Gilead Sciences
GILD
$140B
| $17.7M | 8.08% | 237,284 -56,000 | -19% | -$4.18M |
|
3
Biogen
BIIB
$19.4B
| $14.5M | 6.59% | 45,700 | – | – |
|
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $14.3M | 6.54% | 169,784 +65,500 | +63% | +$5.53M |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $14.2M | 6.49% | 337,000 +1,000 | +0.3% | +$42.2K |
|
6
Amgen
AMGN
$155B
| $13.4M | 6.1% | 66,000 | – | – |
|
|
7
PTC Therapeutics
PTCT
$3.92B
| $12M | 5.46% | 269,000 +155,000 | +136% | +$6.9M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $11.7M | 5.32% | 394,000 +4,000 | +1% | +$118K |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $9.29M | 4.23% | 107,300 -26,000 | -20% | -$2.25M |
|
|
CCXI
10
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.63M | 3.48% | +190,000 | New | +$7.63M |
|
11
Incyte
INCY
$16.5B
| $7.29M | 3.32% | 99,500 +35,500 | +55% | +$2.6M |
|
|
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
| $6.96M | 3.17% | 281,797 +239,097 | +560% | +$5.9M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $6.61M | 3.01% | 73,641 -12,500 | -15% | -$1.12M |
|
|
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.56M | 2.99% | 56,900 -7,100 | -11% | -$818K |
|
15
Merck
MRK
$210B
| $6.4M | 2.92% | 83,200 +200 | +0.2% | +$15.4K |
|
16
Halozyme
HALO
$8.56B
| $5.53M | 2.52% | 307,633 | – | – |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.37M | 1.54% | 43,900 +8,000 | +22% | +$615K |
|
|
18
Eli Lilly
LLY
$657B
| $2.77M | 1.26% | +20,000 | New | +$2.77M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $2.74M | 1.25% | 28,100 -12,000 | -30% | -$1.17M |
|
20
Ionis Pharmaceuticals
IONS
$6.79B
| $2.54M | 1.16% | 53,781 | – | – |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $2.43M | 1.11% | 22,300 -21,000 | -48% | -$2.28M |
|
22
Enanta Pharmaceuticals
ENTA
$180M
| $2.39M | 1.09% | +46,500 | New | +$2.39M |
|
23
Exelixis
EXEL
$10.1B
| $1.78M | 0.81% | 103,534 | – | – |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $1.73M | 0.79% | 227,433 -50,000 | -18% | -$381K |
|
|
XLRN
25
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.62M | 0.74% | 18,000 -39,000 | -68% | -$3.5M |
|